Stemirna Therapeutics Co., Ltd.

Stemirna (Shanghai) Biotechnology Co. Lted.

Dean G Tang

Xin Chen

Ruifang Liu

Can Liu

The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.

Formulations and methods for the treatment of cancers

Provided herein are methods of treating a cancer in an individual. A microRNA-199a oligonucleotide or mimic that increases the expression of microRNA-199a in the cancer cell is administered to the individual. Also provided is a method of inhibiting proliferation of a cancer cell and treating a cell associated with a cancer. The cell is contacted with the microRNA-199a oligonucleotide or mimic.

Methods of using microRNA-199A

Provided herein are methods of treating a cancer in an individual. A microRNA-141 oligonucleotide or mimic that increases the expression of microRNA-141 in the cancer cell is administered to the individual. Also provided is a method of inhibiting proliferation of a cancer cell and treating a cell associated with a cancer. The cell is contacted with the microRNA-141 oligonucleotide or mimic.

Growing community of inventors

Williamsville, NY, United States of America

Dean G Tang